• Product NameLenvatinib (E7080)
• Brief DescriptionInhibitors
• Purification98.57%
• Biological ActivityLenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.
• Target NameFGFR inhibitor; PDGFR inhibitor; VEGFR inhibitor
• CAS No. 417716-92-8
• Calculated MW 426.85
• Formulation C21H19ClN4O4
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4CC4)C=C3)=C2C=C1C(N)=O
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:FGFR1; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4
  Boling pt:
  Melting pt:
  Solubility:DMSO: 40 mg/mL (93.7 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Matsui J, et al. Int J Y. 2008, 122(3), 664-671.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting